dipyridamole has been researched along with Autosomal Recessive Chronic Granulomatous Disease in 1 studies
Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Muneuchi, J | 1 |
| Ishimura, M | 1 |
| Takada, H | 1 |
| Hoshina, T | 1 |
| Utsunomiya, R | 1 |
| Ikeda, K | 1 |
| Yamaguchi, K | 1 |
| Ohga, S | 1 |
| Kusuhara, K | 1 |
| Hara, T | 1 |
1 other study available for dipyridamole and Autosomal Recessive Chronic Granulomatous Disease
| Article | Year |
|---|---|
Incomplete Kawasaki disease in a patient with chronic granulomatous disease.
Topics: Aspirin; Child, Preschool; Coronary Aneurysm; Coronary Angiography; Dipyridamole; Follow-Up Studies; | 2010 |